Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey

Abstract

Background: Underestimation of relapse in multiple sclerosis (MS) is detrimental to the patient as well as to their relationship with their MS healthcare professional (HCP). Objective: To obtain direct insight into relapse prevalence, symptoms, and HCP engagement from patients with MS who responded to the Multiple Sclerosis in America (MSIA) 2017 survey. Methods: Information on patient demographics, health insurance coverage, symptoms, disability, relapses, and related HCP interactions were captured. Descriptive analyses were conducted and relapses were annualized. Chisquare tests were used to evaluate frequency of patient engagement, i.e. speaking with or seeing their HCP during relapse with annualized relapse frequency and topics discussed. Results: Of the 5,311 patient-respondents, the mean age was 51.2 years (84.3% female, 89.3% Caucasian); 40.1% were on disability, and 96.8% had health insurance coverage. A total of 72.2% of patients were diagnosed with relapsingremitting MS (RRMS); 74.8% of patients not reporting a diagnosis of primary progressive MS (PPMS) (n = 4819) were using disease-modifying therapy. In the 2 years preceding the survey, 73.1% experienced a relapse for a median number of 2 relapses; this corresponded to an annualized relapse distribution among all patients of 44.1% with < 1 relapse, 35.5% with 1-2 relapses, and 20.2% with > 2 relapses. In patients reporting relapses, 62.5% cited an average relapse duration of < 1 month, 10.9% cited 1-2 months, and 13.6% cited > 2 months (12.9% were unsure/didn't recall). Leading symptoms experienced with MS relapse were fatigue (77.4%), numbness/tingling (70.0%), and walking or balance issues (68.8%). With respect to HCP engagement during relapse, 46.9% of patients reported doing so always/often, vs. sometimes (27.3%), rarely (18.5%), and never (7.3%). The most common reasons cited for not engaging an HCP were that the relapse was not severe enough (57.9%), the HCP was unhelpful or didn't specifically tell the patient to contact them (30.9%), the treatment didn't work well or wasn't tolerated (25.6%), or the preference to manage alone (24.4%). A higher percentage of patients with 1 relapse coincided with the highest frequency of HCP engagement during relapse, and the highest percentage of patients with ≥ 5 relapses coincided with the lowest frequency of HCP engagement during relapse. Key relapse-related and MS-related topics were discussed more by patients who always/often engage their HCP during relapse. HCP follow-up after relapse was variable, with 35.0% of patients reporting follow-up within 1 month of first contact, 50.3% reporting follow-up at the next office visit, and 14.7% reporting no follow-up. Conclusion: MS relapse remains particularly challenging for certain patients; some experience > 2 relapses in 1 year, relapse durations > 1 month, and relapse symptoms that interfere with daily functioning (e.g. walking/ balance by 68.8%). Approximately 25% of patients reported rarely or never engaging their HCP during relapse. Common reasons for not e...

Treatment Effectiveness for Resolution of Multiple Sclerosis Relapse in a US Health Plan Population

“…This rate is higher than usually reported by other publications, which can calculate ARR differently, i.e., among all MS patients regardless of the incidence of relapse and length of follow-up [28–30]. Other research also illustrates variable relapse frequency among patients, i.e., with one study indicating > 20% of relapsing patients reporting more than two relapses in a year [31]. Of patients who experienced relapse in our study, over one-third experienced at least one unresolved relapse and required additional healthcare visits and relapse treatments within 30 days to resolve their relapse.…”

Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS)

“…Follow-up interval is important when determining outcomes because visit frequency may influence observed event frequency, depending on how the information is captured. For example, individuals with MS may not always present to the physician during a relapse (38).…”

Beneficial Roles of Microglia and Growth Factors in MS, a Brief Review

“…This form is characterized by acute demyelinating phase, corresponding to an attack on myelin and nerve fibers by immune cells, followed by periods of remission (Ghasemi et al, 2017 ). Usually, it lasts 5–10 years and evolves in 80% of cases in secondary chronic–progressive phase (Nazareth et al, 2018 ). The neuroinflammation and by extension damages in the CNS are due to immune cell activation and their cytokines, resulting in the formation of plaques composed of cells, demyelinated axons, and astrogliosis in the white and gray matter (Compston and Coles, 2008 ).…”